ACTINIUM PHARMACEUTICALS, INC. (ATNM)

Every figure this model derived for ATNM, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 104,000 PaymentsToAcquirePropertyPlantAndEquipment 2025-12-31
cash 36,473,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 37,740,000 AssetsCurrent 2026-06-30
current liabilities 9,260,000 LiabilitiesCurrent 2026-06-30
equity 30,302,000 StockholdersEquity 2026-06-30
ocf -22,663,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 35,000,000 RevenueFromContractWithCustomerIncludingAssessedTax 2026-06-30
sbc 248,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up ATNM on one particular measure came for.

RatioValue
cash operating margin28.51
current ratio4.08
current ratio reported4.08
deferred revenue growth-50.0
dilution pct3.75
fcf margin-65.05
operating margin27.3
owner earnings margin-65.76
sbc pct revenue0.71

What to be careful about

What this model itself distrusts about ATNM's figures. Written by the derivation as it ran, not added afterwards.